Search
KDT-3594
go.drugbank.com/drugs/DB17085InvestigationalKDT-3594 is a non-ergot dopamine receptor agonist developed by Kissei Pharmaceutical.
MEM 1414
go.drugbank.com/drugs/DB05888ExperimentalMEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of the brain where new memories are formed.
Bendazac
go.drugbank.com/drugs/DB13501ApprovedWithdrawnBendazac is an oxyacetic acid . Despite possessing anti-inflammatory, anti-necrotic, choleretic, and anti-lipidemic characteristics, most research has revolved around studying and demonstrating the agent's principal action in inhibiting ...
Arotinolol
go.drugbank.com/drugs/DB09204Investigational[T87] Artinolol is being developed by Sumitomo Pharmaceutical Co., Ltd. and it is currently under clinical trials.[L1168]
AM103
go.drugbank.com/drugs/DB05225ExperimentalIt is being developed by Amira. … AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation
AC3056
go.drugbank.com/drugs/DB05230ExperimentalIt as since been acquired by Amylin Pharmaceuticals and has completed phase I trials. … AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals.
Smilagenin
go.drugbank.com/drugs/DB05450InvestigationalSmilagenin is a novel non-peptide, orally bioavailable neurotrophic factor inducer that readily reverses free radical neurotoxicity produced by 1-ethyl-4- phenylpyridium (MPP+) in dopaminergic neurones … P58 is a protein synthesis stimulant acts by restoring levels of proteins that are altered in the ageing brain, reversing the loss of nerve receptors in the ageing brain and potentially allowing for the
Tenamfetamine
go.drugbank.com/drugs/DB01509IllicitInvestigationalIt is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem]
Entrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.
Hydroxyzine
go.drugbank.com/drugs/DB00557ApprovedInvestigational[A189753] Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety.[L9677]